Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
3,182,163
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
42,200,841
-
Shares change
-
-591,864
-
Total reported value, excl. options
-
$99,586,412
-
Value change
-
-$2,254,627
-
Number of buys
-
34
-
Number of sells
-
-65
-
Price
-
$2.36
Significant Holders of Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) as of Q2 2022
110 filings reported holding PASG - Passage BIO, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42,200,841 shares
.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8,931,999 shares), Frazier Life Sciences Management, L.P. (5,009,219 shares), Versant Venture Management, LLC (4,959,769 shares), New Leaf Venture Partners, L.L.C. (2,497,922 shares), Deep Track Capital, LP (2,320,000 shares), VANGUARD GROUP INC (1,843,513 shares), Woodline Partners LP (1,788,059 shares), BlackRock Inc. (1,368,347 shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (1,235,869 shares), and Erste Asset Management GmbH (1,170,800 shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.